92 - Obeldesivir Reduced SARS-CoV-2 Infectious Titers in the BIRCH Phase 3 Clinical Trial

Thursday, October 17, 2024

11:30 AM – 11:43 AM US PT

Location: 411

Presenting Author(s)

Lauren Rodriguez, PhD

Research Scientist
Gilead Sciences, Inc.
Foster City, CA, United States

Slides

Co-Author(s)

Anca Streinu-Cercel, MD PhD Prof. Infectious Diseases (she/her/hers)

Chef of Infectious Diseases Unit 5 at Matei Bals National Infectious Diseases Institute
"Prof. Dr. Matei Bals" National Institute for Infectious Diseases Carol Davila Medicine and Pharmacy University
Bucharest, Bucuresti, Romania
JG

Juan M. Gonzalez Del Castillo, MD, PhD

Emergency Department, Hospital Clínico Universitario San Carlos
Madrid, Madrid, Spain
YK

Yiannis Koullias, MD

Gilead Sciences, Inc.
Foster City, California, United States
AM

Afsaneh Mozaffarian, MS

Gilead Sciences, Inc.
Foster City, California, United States
KE

Kim Etchevers, MS

Gilead Sciences, Inc.
Foster City, California, United States
SC

Shuguang Chen, PhD

Director
Gilead Sciences, Inc
Foster City, California, United States
RH

Robert H. Hyland, DPhil

Gilead Sciences, Inc.
Foster City, California, United States
JL

Joe Llewellyn, PharmD (he/him/his)

Clinical Development
Gilead Sciences, Inc.
Foster City, California, United States
RG

Romas Geleziunas, PhD

Gilead Sciences Inc.
Foster City, California, United States
LF

Leon Fouche, MBChB

Limpopo Clinical Research Initiative
Thabazimbi, Limpopo, South Africa
SC

Shan-Chwen Chang, MD, PhD

Professor
National Taiwan University Hospital
Taipei, Taipei, Taiwan (Republic of China)
AC

Antonella Castagna, MD

Investigator
IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University
Milano, Lombardia, Italy
Charlotte Hedskog, PhD (she/her/hers)

Senior Research Scientist
Gilead Sciences, Inc.
Foster City, California, United States

Disclosure(s):

Lauren Rodriguez, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Anca Streinu-Cercel, MD PhD Prof. Infectious Diseases: Gilead Sciences, Inc.: Grant/Research Support, Honoraria

Juan M. Gonzalez Del Castillo, MD, PhD: No financial relationships to disclose

Yiannis Koullias, MD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Afsaneh Mozaffarian, MS: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Kim Etchevers, MS: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Shuguang Chen, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Robert H. Hyland, DPhil: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Joe Llewellyn, PharmD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Romas Geleziunas, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Leon Fouche, MBChB: No financial relationships to disclose

Shan-Chwen Chang, MD, PhD: No financial relationships to disclose

Antonella Castagna, MD: Bristol-Myers Squibb: Advisor/Consultant; Gilead Sciences, Inc.: Advisor/Consultant, Grant/Research Support, Honoraria; Janssen: Advisor/Consultant, Grant/Research Support, Honoraria; Merck Sharp & Dohme: Advisor/Consultant, Grant/Research Support, Honoraria; ViiV Healthcare: Advisor/Consultant, Grant/Research Support, Honoraria

Charlotte Hedskog, PhD: Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)